Detail akcie Ginkgo Bio Rg-A online

Business Summary: Ginkgo Bioworks Holdings, Inc. offers biological research and development (R&D) services on its platform and autonomous laboratory to enable its customers to bring their products to market. The Company sells tools and biological R&D services across a range of industries to government and commercial customers. Its in-house autonomous lab is available as Cloud Lab through its Datapoints and Solutions contract research services. Its single segment, namely cell engineering, provides tools and biological R&D services across a range of industries. Its cell engineering customers work with biology to discover and manufacture new products across industries such as medicine, agriculture, industrial biotechnology and government. It provides R&D services spanning genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics. It provides a suite of microservices for product developers across industries that support bioengineers with protein engineering.
Financial Summary: BRIEF: For the three months ended 31 March 2026, Ginkgo Bioworks Holdings Inc revenues decreased 49% to $19.5M. Net loss before extraordinary items decreased 9% to $76.1M. Revenues reflect United States segment decrease of 52% to $16.3M, Denmark segment decrease of 30% to $3.2M. Lower net loss reflects Autonomous Lab segment loss decrease of 12% to $71.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.54 to -$1.28.